| Literature DB >> 17355637 |
Andreas R Pfenning1, Russell Schwartz, Alison L Barth.
Abstract
BACKGROUND: Neuronal activity regulates gene expression to control learning and memory, homeostasis of neuronal function, and pathological disease states such as epilepsy. A great deal of experimental evidence supports the involvement of two particular transcription factors in shaping the genomic response to neuronal activity and mediating plasticity: CREB and zif268 (egr-1, krox24, NGFI-A). The gene targets of these two transcription factors are of considerable interest, since they may help develop hypotheses about how neural activity is coupled to changes in neural function.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17355637 PMCID: PMC1831778 DOI: 10.1186/1471-2202-8-20
Source DB: PubMed Journal: BMC Neurosci ISSN: 1471-2202 Impact factor: 3.288
Figure 1Activity dependent transcription factor binding sites consensus sequences. The height of the letters is proportional to their frequency in the data used to build the matrix. For instance, a large "A" in position one means that "A" belongs to the most probable consensus for that transcription factor binding site. (A) Consensus sequence given by the transfac CRE-binding matrix V$CREB_01. (B) Consensus sequence given by the transfac zif268 binding matrix V$EGR1_01.
Scores of computational search for activity-dependent transcription factor binding sites
| Mouse | Human | Homologuea | |||||||
| Measure | Promoterb | Intergenicc | Scored | Promoterb | Intergenicc | Scored | Completee | Conservedf | Scoreg |
| Total genes | 18071 | 13475 | 19794 | 15178 | 13365 | 516 | |||
| CREB targets | 1050 | 279 | 0.64 | 1389 | 388 | 0.64 | 830 | 356 | 0.83 |
| zif268 targets | 1382 | 200 | 0.81 | 1203 | 244 | 0.74 | 1136 | 166 | 0.56 |
| % CREB genes | 5.81% | 2.07% | 7.02% | 2.56% | 6.21% | 2.66% | |||
| % zif268 genes | 7.65% | 1.48% | 6.08% | 1.61% | 8.50% | 1.24% | |||
a The homologue dataset was contructed using the Homologene resource on the NCBI website ().
b The promoter region is the area from -1,000 to 200 bp relative to transcription start.
c Intergenic regions refer to an area 50,000 bp away from transcription start. Fewer intergenic regions are available than genes because of gaps in sequencing.
d The score is determined by the positive predictive value which is a conservative estimate of the fraction of found transcription factor binding sites that are true hits. It is calculated as (%Observed - %Intergenic)/(%Observed).
eThe complete homologue numbers refer the the number of human/mouse homologous pairs identified using the Homologene resources.
f The conserved dataset is a subset of the Homologene dataset that consists of only those genes for which homologous pairs contain a conserved binding site.
g The quality is determined by the positive predictive value which is a conservative estimate of the percentage of found transcription factor binding sites that are true hits. It is calculated as (%Conserved Observed - %Predicted Conserved)/(%Conserved Observed).
Figure 2Relative frequency of transcription factor binding sites within promoter regions across species. (A) The percentage of human, mouse, and rat promoters with a predicted CREB binding site. (B) The same as (A), but for zif268. (C) The percent of genes within the homologene dataset showing a CREB or zif268 site, calculated by (# of promoters with a binding site × 100)/(# of human and mouse homologous pairs).
Figure 3CREB and zif268 binding sites show strong location specificity. All histograms were created using a bin size of 50 bp. The total number of binding sites in each 50 bp region was divided by the total number of promoters for that dataset. Shown are both human (red) and mouse (blue) and promoters. For the intergenic dataset, the area shown is from -51,200 bp to -50,000 bp relative to transcription start. The mouse dataset is the location of mouse binding sites when the homologous gene also has a binding site of the same type. The human dataset is the location of human binding sites when the homologous gene also has a binding site of the same type. A) Promoters with a CREB binding site are grouped by position relative to transcription start, showing pronounced location specificity within the promoter. (B) The same as (A) but for zif268. (C) The same as (A) but for the conserved CREB targets in the mouse-human homogene dataset. (D) The same as (A) but for the conserved zif268 targets in the mouse-human homogene dataset. The percentage of promoters with a binding site is calculated relative to the total number of homologous pairs.
Figure 4Binding site location in CREB/zif268 double hits. Promoter regions for the genes on the line to the left are from -1000 bp to 200 bp relative to transcription start, which is denoted by the arrow. The red blocks above represent CREB binding sites while the green blocks represent zif268 binding sites. Mouse transcription factor binding sites are found on top of the line while human sites are below. A non-alignment method was used to identify promoter regions, so homologous binding sites might not be at the same location. Gene symbols shown are those for mouse. Promoter regions shown are for (A) FBJ osteosarcoma oncogene B/FosB, (B) Jun proto-oncogene related gene d1 (C) v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian), (D) SKI-like, (E) neuronal pentraxin 1, and (F) tropomyosin 4. The targets in the yellow box represent transcription factors.
Experimental support for binding site activity
| activity-related cytoskeletal protein | arc | zif268 | n/ab | [83] | |
| BDNF | bdnf | CREB | n/ac | [84, 85] | |
| beta-polymerase | polb | CREB | CREB | C | [86] |
| cathepsin L | ctsl | CREB | CREB | C | [87] |
| c-fos | fos | CREB | CREB | M | [88, 89] |
| early response gene 3 | egr3 | zif268 | CREB | M | [90] |
| fibronectin | fn1 | CREB | CREB | M | [91] |
| glycoprotein hormone alpha | cga | CREB | CREB | Hd | [62] |
| Ngfi-A binding protein 2 | nab2 | zif268 | zif268 | C | [90] |
| proteasome subunit, alpha type 5 | psma5 | zif268 | zif268 | M | [92] |
| protein phosphatase 2a, catalytic | ppp2ca | CREB | CREB | C | [93] |
| S100B | s100b | CREB | CREB | C | [94] |
| somatostatin | sst | CREB | CREB | C | [58] |
| steroid 11-beta hydroxylase | cyp11b1 | CREB | CREB | C | [95] |
| synapsin I | syn1 | zif268 | CREB | M | [96, 97] |
| synapsin II | syn2 | zif268 | zif268 | C | [61] |
| transporter associated with antigen processing 2 | tap2 | zif268 | zif268 | M | [92] |
| tropomyosin 1, alpha | tpm1 | CREB | CREB+zif268 | M | [37] |
| tyrosine hydroxylase | th | CREB | CREB | C | [59, 60] |
| vasoactive intestinal peptide | vip | CREB | CREB | C | [98] |
a Mouse (M), Human (H), or Conserved (C) homologene dataset where a putative binding site was found
bA zif268 site in the mouse arc gene was identified in an earlier version of the search, but following an important correction for GC content in the gene promoter this site was no longer recognized
c The CREB site in promoter I that has been well-characterized in rat (Tabuchi et al. 2002) did not qualify as having a binding site by the quality score criterion used in this analysis
d Glycoprotein hormone alpha has a well documented CREB site in human that is absent in rodents based on a single bp mutation
Overlapping regulatory targets: comparison with other studies
| Symbol | Gene Name | Accession #a | Conserved siteb | Type of studyc | Reference |
| Clcn3 | chloride channel 3 | NM007711 | CREB | ChIP/SACO | 25 |
| Cycs | cytochrome c, somatic | NM007808 | CREB | ChIP/SACO | 25 |
| Fn1 | fibronectin 1 | AK147683 | CREB | ChIP/SACO | 25 |
| FosB | FosB | NM008036 | CREB | ChIP/SACO | 25 |
| Ldh1 | lactate dehydrogenase 1, A chain | BC066858 | CREB | ChIP/SACO | 25 |
| Mlf2 | myeloid leukemia factor 2 | NM145385 | CREB | ChIP/SACO | 25 |
| Nf1 | neurofibromatosis 1 | NM010897 | CREB | ChIP/SACO | 25 |
| Ppargc2 | peroxisome proliferative activated receptor, gamma, coactivator 1 alpha | NM008904 | CREB | ChIP/SACO | 25 |
| Sstr2 | somatostatin receptor 2 | NM009217 | CREB | ChIP/SACO | 25 |
| St13 | suppression of tumorigenicity 13 | NM133726 | CREB | ChIP/SACO | 25 |
| Socs7 | suppressor of cytokine signaling 7 | NM138657 | CREB | ChIP/SACO | 25 |
| TpT1 | tumor protein, translationally-controlled 1 | NM009429 | CREB | ChIP/SACO | 25 |
| JunD1 | Jun proto-oncogene related gene d1 | NM010592, 16478 | CREB | ChIP/SACO, CREB overexpression | 25, 37 |
| Maff | v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) | NM_010755, 17133 | CREB | ChIP/SACO, CREB overexpression | 25, 37 |
| Arg2 | arginase type II | 11847 | CREB | CREB overexpression | 37 |
| Avpi1 | arginine vasopressin-induced 1 | 69534 | CREB | CREB overexpression | 37 |
| Arih1 | ariadne ubiquitin-conjugating enzyme E2 binding protein homolog 1 (Drosophila) | 23806 | CREB | CREB overexpression | 37 |
| Cd2ap | CD2-associated protein | 12488 | CREB | CREB overexpression | 37 |
| Dhx36 | DEAH (Asp-Glu-Ala-His) box polypeptide 36 | 72162 | CREB | CREB overexpression | 37 |
| Dusp1 | dual specificity phosphatase 1 | 19252 | CREB | CREB overexpression | 37 |
| Ell2 | elongation factor RNA polymerase II 2 | 192657 | CREB | CREB overexpression | 37 |
| AW050020 | expressed sequence AW050020 | 268420 | CREB | CREB overexpression | 37 |
| Foxd3 | forkhead box D3 | 15221 | CREB | CREB overexpression | 37 |
| Gem | GTP binding protein (gene overexpressed in skeletal muscle) | 14579 | CREB | CREB overexpression | 37 |
| Mcm2 | minichromosome maintenance deficient 2 mitotin (S. cerevisiae) | 17216 | CREB | CREB overexpression | 37 |
| Mlf1 | myeloid leukemia factor 1 | 17349 | CREB | CREB overexpression | 37 |
| Myh10 | myosin, heavy polypeptide 10, non-muscle | 77579 | CREB | CREB overexpression | 37 |
| Nek1 | NIMA (never in mitosis gene a)-related expressed kinase 1 | 18004 | CREB | CREB overexpression | 37 |
| Pde7a | phosphodiesterase 7A | 18583 | CREB | CREB overexpression | 37 |
| Psmb8 | proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7) | 16913 | CREB | CREB overexpression | 37 |
| 2700085E05Rik | RIKEN cDNA 2700085E05 gene | 67201 | CREB | CREB overexpression | 37 |
| 4933407C03Rik | RIKEN cDNA 4933407C03 gene | 74440 | CREB | CREB overexpression | 37 |
| 6330407G11Rik | RIKEN cDNA 6330407G11 gene | 68050 | CREB | CREB overexpression | 37 |
| Rbms2 | RNA binding motif, single stranded interacting protein 2 | 56516 | CREB | CREB overexpression | 37 |
| St7 | Suppression of tumorigenicity 7 | 64213 | CREB | CREB overexpression | 37 |
| Tgif2 | TGFB-induced factor 2 | 228839 | CREB | CREB overexpression | 37 |
| Trip6 | thyroid hormone receptor interactor 6 | 22051 | CREB | CREB overexpression | 37 |
| Tle3 | transducin-like enhancer of split 3, homolog of Drosophila E(spl) | 21887 | CREB | CREB overexpression | 37 |
| Tpm4 | tropomyosin 4 | 326618 | CREB | CREB overexpression | 37 |
| Trp53inp2 | tumor protein p53 inducible nuclear protein 2 | 68728 | CREB | CREB overexpression | 37 |
| Th | tyrosine hydroxylase | 21823 | CREB | CREB overexpression | 37 |
| Wbp5 | WW domain binding protein 5 | 22381 | CREB | CREB overexpression | 37 |
| Xpr1 | xenotropic and polytropic retrovirus receptor 1 | 19775 | CREB | CREB overexpression | 37 |
| Znrd1 | zinc ribbon domain containing, 1 | 66136 | CREB | CREB overexpression | 37 |
| Sgta | small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha | NM024499 | Zif268 | Zif268 overexpression | 57 |
aAccession numbers for CREB overexpression experiments are the GeneID, not the mRNA acession number.
bGene target had a conserved mouse-human transcription factor binding site in the promoter region and was also identified in the referenced study.
cType of experimental analysis carried out in the referenced study. ChIP indicated chromatin immunoprecipitation followed by a serial analysis of chromatin occupancy in DNA isolated from rat PC12 cells that had been stimulated with forskolin to increase intracellular cAMP 15 minutes prior to DNA extraction [25]. Zif268 overexpression refers to studies where zif268 was overexpressed in PC12 cells, and RNA was extracted 48 hrs post-transfection [57]. CREB overexpression refers to studies where a super-active form of CREB is expressed in mice for 1 to 5 weeks. RNA is extracted from hippocampus and run on Affymetrix GeneChip Murine Genome U74 Version 2 Set MG-U74A [37]. Our analysis of the data was done using GSEA as described in the methods.